argenx SE at JPMorgan Healthcare Conference Transcript
&-
Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, it's my pleasure to introduce the argenx presentation, and you're going to hear from argenx CEO, Tim Hauwermeiren. And we have the breakout in here as well, so 20 minutes presentation and then time for your questions. So thanks a lot for joining us today, Tim.
Good morning, everyone, and warm welcome to the argenx implementation. And whilst we take a look at the forward-looking statements, James, I would like to thank you for hosting us today at this wonderful conference.
We at argenx, we're on a bold journey, a journey to transform autoimmunity. Actually, we want to take autoimmunity away from surgery and blunt chemotherapy into precision medication, where we basically nail with precision tools, specific molecular pathways, which drive disease, offering a radically different benefit risk profile to patients, a transformative benefit to patients.
And
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
